0
Skip to Content
Drug Discovery services
Services
About
Contact
Book now
Drug Discovery services
Services
About
Contact
Book now
Services
About
Contact
Book now

Proven drug discovery leader with over 20 years of experience advancing innovative therapies from concept to clinic. Track record includes 8 IND filings and one FDA-approved medicine (Revumenib), with deep expertise across small molecules, peptide therapeutics, and emerging modalities.I have led programs from target validation through hit identification and optimization, using cutting-edge approaches such as SBDD, FBDD, HTS, DEL, and non-classical modalities including PROTACs, molecular glues, covalent inhibitors, and allosteric modulators. My peptide experience spans enkephalin analogs, VLA4 antagonists, and PCSK9 inhibitors.T herapeutic expertise covers a broad range of diseases—Alzheimer’s, Parkinson’s, stroke, neuropathic pain, cancer, immunology, virology, and osteoporosis—working on diverse targets including proteases, GPCRs, ion channels, PPIs, and inflammasomes. I have consistently addressed key challenges in potency, selectivity, ADME, cardiovascular liabilities, and toxicity, leading to successful development candidates.In addition to discovery science, I have optimized synthetic routes for bulk API production and directed outsourcing/scale-up strategies. I bring strong interdisciplinary knowledge across biophysics, pharmacology, biology, ADME, and formulation. I am an inventor on 30 issued U.S. patents with 40 additional applications pending.

Leadership & Business Impact

  • 10+ years of leadership experience, managing multidisciplinary teams (chemistry, DMPK, pharmacology) in matrix environments.

  • Directed programs resulting in $500M in upfront deal value and over $2B in potential milestones.

  • Extensive experience managing strategic collaborations (e.g., Boehringer Ingelheim, Merck) and external CRO networks (chemistry, DMPK, HTS).

  • Skilled in setting R&D strategy, budget, and timelines, ensuring on-time delivery of milestones.

  • Certified in Project Management and QA/RA for drug development, bridging science with regulatory and business objectives.

Who We Are

At ShankarV Rx LLC, we bring over 20 years of proven leadership in drug discovery. From 7 IND filings to an FDA-approved therapy (Revumenib), we’ve successfully advanced programs across oncology, neurology, immunology, and metabolic diseases. Our consulting services are designed to help you overcome bottlenecks, optimize strategies, and maximize R&D investments.

What We Do

  • Target Selection & Validation

    Confidently choose the right targets with in-depth scientific and clinical assessments.

  • Hit Identification & Optimization

    Expertise in SBDD, FBDD, HTS, DEL, and cheminformatics to find high-quality leads quickly.

  • Lead Optimization

    Driving molecules to candidates through SAR, potency, selectivity, and ADMET balance.

  • Preclinical Strategy

    Translational study design that bridges discovery with IND-enabling development.

  • Innovative Modalities

    PROTACs, molecular glues, cyclic peptides, covalent/allosteric modulators.

  • Data & Portfolio Review

    Integrating chemistry, biology, DMPK, and safety to prioritize next steps.

Why Work With Us-Proven Impact

  • ✅ 7 INDs Filed

  • ✅ 1 FDA-Approved Drug

  • ✅ $700M+ in upfront deals

  • ✅ $2B+ in milestone potential

  • ✅ 20+ years of global pharma & biotech leadership

Testimonials / Client Success

“ShankarV Rx LLC provided the clarity and strategy we needed to push our lead program forward. Their insights into medicinal chemistry and translational strategy were invaluable.”

— Biotech CEO, Oncology

Shankar is one of the most creative Chemists I met in my career as Medicinal Chemist. He has a deep understanding of all aspects of Drug Discovery including drug design, SAR, synthesis, pharmacology, pharmacokinetics and selecting the right molecules for profiling. It was a pleasure to work with him. He is a team player, excellent communicator and is driven by project success.

—-
Klaus Fuchs: Senior Research Project Leader at Boehringer Ingelheim Pharma